- Center on Health Equity & Access
- Clinical
- Health Care Cost
- Health Care Delivery
- Insurance
- Policy
- Technology
- Value-Based Care
PAPER OF THE WEEK: From 2015, Treatments That Prevent Heart Failure Miss Medicaid Patients
The paper appeared a few months before the EMPA-REG OUTCOME trial revealed the potential of a new drug class, the SGLT2 inhibitors, in preventing hospitalization for heart failure.
Welcome to Paper of the Week, which looks back at research and commentary of the past 25 years in The American Journal of Managed Care® and why it matters today.
This week’s paper comes from our January 2015 issue. The authors of “Disease-Modifying Therapy and Hospitalization Risk in Heart Failure Patients” discuss the high cost of heart failure to the health system. They found that some treatments, such as ACE inhibitors or ARBs, had potential in preventing heart failure in Medicaid patients in managed care, but the projected savings were relatively modest.
The paper appeared a few months before the EMPA-REG OUTCOME trial revealed the potential of a new drug class, the SGLT2 inhibitors, in preventing hospitalization for heart failure.
For the full paper, visit ajmc.com.
What It Takes to Improve Guideline-Based Heart Failure Care With Ty J. Gluckman, MD
August 5th 2025Explore innovative strategies to enhance heart failure treatment through guideline-directed medical therapy, remote monitoring, and artificial intelligence–driven solutions for better patient outcomes.
Listen
ATTR-CA Variant Disproportionately Impacts Black Individuals With Heart Failure
September 16th 2025The transthyretin cardiac amyloidosis (ATTR-CA) variant is more prevalent in Black individuals, increasing the need for more research to assess hereditary links and early prevention awareness.
Read More
